Long-Term Survival and Recurrence After Acute Myocardial Infarction in England, 2004 to 2010

Abstract

Background— There are limited population-based national data on prognosis in survivors of acute myocardial infarction (AMI), particularly on long-term survival and the risk of recurrence. Methods and Results— Record linkage of hospital and mortality data identified 387 452 individuals in England who were admitted to hospital with a main diagnosis of AMI between 2004 and 2010 and who survived for at least 30 days. Seven years after an AMI, the risk of death from any cause in survivors of first or recurrent AMI was, respectively, 2 and 3 times higher than that in the English general population of equivalent age. For all survivors of a first AMI, the risk of a second AMI was highest during the first year and the cumulative risk increased more gradually thereafter. For men, 1- and 7-year cumulative risks were 5.6% (95% confidence interval [CI], 5.5–5.7) and 13.9% (95% CI, 13.7–14.1); for women, they were 7.2% (95% CI, 7.1–7.4) and 16.2% (95% CI, 16.0–16.5). Older age, higher deprivation, no revascularization procedures, and presence of comorbidities were associated with higher recurrence risk. Conclusions— Survivors of both first and recurrent AMI remained at a significantly higher risk of death compared with the general population for at least 7 years after the event. For survivors of first AMI, the influence of predisposing factors for second AMI lessened with time after the initial event. The results reinforce the importance of acute clinical care and secondary prevention in improving long-term prognosis of hospitalized AMI patients.

Long‐Term Mortality of Older Patients With Acute Myocardial Infarction Treated in US Clinical Practice

“…A British study evaluated long‐term survival of patients with MI who survived at least 30 days post‐index event. The median age of that study population was 71 years, and the 7‐year survival was 69% among men and 53% among women 13. In our landmark analysis conditioned upon surviving 1 year post‐MI, we observed an 8‐year mortality rate of 59%.…”

Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

“…Despite improvements in survival after the first and recurrent acute MI over the last three decades, individuals remain at high risk for recurrent events and death. A recent record linkage study [8] of long-term prognosis in England found that 86% of patients admitted to hospital for acute MI between 2004 and 2010 survived for at least 30 days. However, the 30 day survivors of both first and recurrent acute MI were, respectively, at 2 and 3 times higher risk of death from any cause compared with the general population for at least 7 years after the event.…”

“…The relative risk was calculated using data from ATLAS-ACS 2-TIMI 51 trial on the relative number of ACS events compared to the number of ACS events in the first 6 months and an estimate of a relative risk after one year based on Smolina et al [8]. The relative risk declined over time so different values were calculated for each of the model tunnel states.…”

Continuous ST‐Monitoring Function of Implantable Cardioverter Defibrillator Detects Silent Ischemia in Patients With Coronary Artery Disease

“…In particular, of those patients who develop a second AMI event, about one‐third will die 7, 8. Prevention of the recurrence of myocardial infarctions in patients with a history of AMI is important for improving prognosis.…”